Scientists achieve milestone in animal-free production of biologics For the first time, scientists have successfully produced sugar-based biologic molecules utilizing bacteria, without the need for animal products. The paper, published in Nature Communications on March 2, describes the production of a common designer polysaccharide, chondroitin sulfate.Read More
Mesoblast gets $110M in financing from investor group Mesoblast has entered into a subscription agreement to form a limited partnership with SurgCenter Development, a U.S.-based investor group, for a total of $110 million via the issue of 60 million shares.Read More
WuXi AppTec acquires Oxgene, adding to its CGT capabilities WuXi AppTec has completed the acquisition of Oxgene, a U.K.-based contract research and development organization that designs and develops scalable gene therapy technologies. The acquisition will allow WuXi to provide its customers with end-to-end support in the creation and development of cell and gene therapies (CGT), according to the company.Read More
Artiva nabs $120M for NK cell therapies Artiva Biotherapeutics has closed $120 million in financing to advance its natural killer (NK) cell therapy development programs and expand ongoing research and development activities.Read More
Jaguar Gene Therapy launches; targets rare genetic diseases Jaguar Gene Therapy has launched after being in stealth mode with the goal of accelerating the development, manufacturing, and commercialization of novel gene therapy treatments for patients suffering from severe genetic diseases.Read More